Omnicell Limited enters into Distributorship Agreement with Hanmi Pharmaceutical for the United Kingdom market

Non-Exclusive distribution agreement for dispensing and packaging automation solution supports the industry vision of the Autonomous Pharmacy and expands Omnicell’s Retail Pharmacy Portfolio in the UK

31 March, 2022 - Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell”), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced Omnicell Limited, a wholly owned subsidiary of Omnicell has entered into an agreement with Hanmi Pharm. Co., Ltd (“Hanmi Pharmaceutical”), to distribute JVM medication dispensing and packaging automation solutions in the United Kingdom (“UK”).

The agreement will build on Omnicell’s current retail pharmacy portfolio of solutions, providing pharmacy owners with a wider range of options for medication adherence blister and pouch packing - which are designed to ensure patients receive the right medication and dose, at the right time.

Across the UK there is increasing pressure on pharmacies to deliver additional services, while still maintaining their prescription and medication adherence services.  This agreement is expected to expand Omnicell’s automated medication adherence portfolio, while providing more choice to meet different needs.

“We think the JVM range of products provides an exceptional new offering for a variety of budgets across the retail pharmacy market, which, in our view, further demonstrates Omnicell’s commitment to understanding and meeting the needs of our clients,” said Sara Dalmasso, general manager and vice president of Omnicell’s international business.

Sara explained, “The last 18-24 months have placed immense pressure on the retail pharmacy sector and we believe this is another step in helping to make the day-to-day working lives of pharmacists easier and more efficient, which should ultimately free up their valuable time to focus more on face-to-face patient interaction and care.”

"Our JVM solution, which is optimized for retail pharmacies, is designed to help pharmacists deliver an enhanced prescribing process and to focus on patient care. We are thrilled to establish a partnership with Omnicell, which has strong expertise in the field of pharmacy automation solutions, to enhance the quality of medication care and to help UK pharmacists." said Mina Son, the director of JVM Global Business at Hanmi Pharmaceutical.

Differentiated Portfolio of Solutions: This agreement is expected to provide new solutions that complement Omnicell’s widely deployed retail pharmacy solutions in the UK, including a pack-pick dispensing robot, automated MDS filling machine, eMAR solution, as well as medication adherence consumables, all of which are designed to help improve medication adherence and health outcomes, while driving pharmacy business results.

Medication dispensing and packaging automation benefits: The JVM solution can automatically sort, distribute and package medications based on customised specifications and removes the need for retail pharmacies to manually handle adherence packaging, which is expected to save time, enabling pharmacists to focus on patient care and developing new revenue-generating healthcare services. Omnicell now offers entry-level solutions for pharmacists with space confinements, to high-volume solutions for pharmacies with greater demand.

Forward-Looking Statements

To the extent any statements contained in this press release deal with information that is not historical, these statements are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, statements including the words “expect,” “intend,” “may,” “will,” “should,” “would,” “could,” “plan,” “potential,” “anticipate,” “believe,” “forecast,” “guidance,” “outlook,” “goals,” “target,” “estimate,” “seek,” “predict,” “project,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to the occurrence of many events outside Omnicell’s control. Such statements include, but are not limited to, those regarding the impact of the distributorship agreement, the expected benefits of the distribution of the JVM product line, and the capabilities of the new products and services (and any implied financial impact). Actual results and other events may differ significantly from those contemplated by forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. These risks and uncertainties include, among other things, (i) risks related to the ongoing COVID-19 pandemic (including new variants of the virus), (ii) Omnicell’s ability to take advantage of growth opportunities and develop and commercialize new solutions and enhance existing solutions, (iii) unfavorable general economic and market conditions or reduction in demand for our solutions, (iv) risks associated with operating in foreign countries, (v) Omnicell’s ability to meet the demands of, or maintain relationships with, its institutional, retail, and specialty pharmacy customers, and (vi) other risks and uncertainties further described in the “Risk Factors” section of Omnicell’s most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q, as well as in Omnicell’s other reports filed with or furnished to the United States Securities and Exchange Commission (“SEC”), available at www.sec.gov. Forward-looking statements should be considered in light of these risks and uncertainties. Investors and others are cautioned not to place undue reliance on forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. Omnicell assumes no obligation to update any such statements publicly, or to update the reasons actual results could differ materially from those expressed or implied in any forward-looking statements, whether as a result of changed circumstances, new information, future events, or otherwise, except as required by law.

ENDS

For additional press information please contact Jo Gulliver at Trinity PR on tel: 02071124905 or email jo.gulliver@trinitypr.co.uk

About Omnicell

Since 1992, Omnicell has been committed to transforming the pharmacy care delivery model to dramatically improve outcomes and lower costs. Through the vision of the autonomous pharmacy, a combination of automation, intelligence, and technology-enabled services, powered by a cloud data platform, Omnicell supports more efficient ways to manage medications across all care settings. Healthcare facilities worldwide use Omnicell automation and analytics solutions to help increase operational efficiency, reduce medication errors, deliver actionable intelligence, and improve patient safety. Institutional and retail pharmacies across North America and the United Kingdom leverage Omnicell's innovative medication adherence and population health solutions to improve patient engagement and adherence to prescriptions, helping to reduce costly hospital readmissions. To learn more, visit www.omnicell.com.

OMNICELL and the Omnicell logo are registered trademarks and Omnicell One is a trademark of Omnicell, Inc. or one of its subsidiaries.

About Hanmi Pharmaceutical and JVM

Hanmi Pharmaceutical is a Korea-based global pharmaceutical company focused on the development and commercialization of new pharmaceutical products. JVM, a global leading provider for pharmacy and hospital automation products, including pouch and blister packagers, was incorporated into Hanmi Pharmaceutical Group in 2016. Since the acquisition, Hanmi Pharmaceutical has been exclusively leading the overseas sales and marketing and managing global partnerships. JVM products and solutions are installed in more than 58 countries worldwide, ensuring the highest patient safety and maximizing pharmacy/hospital workflow efficiency through continuous innovations. To learn more, visit www.hanmipharm.com and  www.myjvm.com/en/